Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
Phase 4
Completed
- Conditions
- Breast CancerBone MetastasisProstate Cancer
- Interventions
- Registration Number
- NCT00334139
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
Bisphosphonates have been used extensively in the treatment and the prevention of skeletal complications associated with bone metastases in patients with breast cancer and prostate cancer.
The purpose of this study is to assess the effect of zoledronic acid patients with prostate cancer or breast cancer and bone metastasis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 411
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description zoledronic acid Zoledronic Acid -
- Primary Outcome Measures
Name Time Method Bone turnover assessed by bone turnover parameters every 30 days
- Secondary Outcome Measures
Name Time Method Correlation between bone complications and bone turnover end of study Correlation between pain and bone turnover at end of study Quality of Life every 30 days Change in prostate specific antigen every 30 days Pain every 30 days
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does zoledronic acid target in bone metastasis from prostate or breast cancer?
How does zoledronic acid compare to other bisphosphonates in preventing skeletal complications in metastatic breast and prostate cancer patients?
Which biomarkers are associated with response to zoledronic acid in bone metastasis of hormone-sensitive prostate or estrogen receptor-positive breast cancer?
What are the long-term adverse events of zoledronic acid in NCT00334139 and how do they compare to denosumab in bone metastasis management?
What combination therapies with zoledronic acid have shown enhanced efficacy in treating bone metastases from prostate or breast cancer compared to monotherapy?
Trial Locations
- Locations (1)
Novartis Investigative Site
🇩🇪Ulm, Germany
Novartis Investigative Site🇩🇪Ulm, Germany